Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingming Yang

Showing results (261-270 of 273) with videos related to

Pageof 28
Sort By:
European Journal of Heart Failure|May 3, 2024
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fractionMingming Yang, Toru Kondo, Atefeh Talebi, et al.
Journal of the American Heart Association|June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global RelevanceMingming Yang, Toru Kondo, Pooja Dewan, et al.
Cancer Cell|December 18, 2020
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor ImmunityChangzheng Lu, Junhong Guan, Steve Lu, et al.
European Journal of Heart Failure|May 16, 2025
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialMisato Chimura, Mingming Yang, Alasdair D Henderson, et al.
Journal of the American College of Cardiology|August 23, 2023
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart FailureToru Kondo, Xiaowen Wang, Mingming Yang, et al.
European Journal of Heart Failure|August 31, 2024
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
European Journal of Heart Failure|June 26, 2024
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fractionMingming Yang, Toru Kondo, Pardeep S Jhund, et al.
Nature Nanotechnology|September 18, 2023
Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeuticsYifan Wang, Weiye Deng, DaeYong Lee, et al.
European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.
Journal of the American College of Cardiology|November 9, 2024
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFMingming Yang, Alasdair D Henderson, Atefeh Talebi, et al.
Pageof 28

Showing results (261-270 of 273) with videos related to

Sort By:
Pageof 28
European Journal of Heart Failure|May 3, 2024
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fractionMingming Yang, Toru Kondo, Atefeh Talebi, et al.
Journal of the American Heart Association|June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global RelevanceMingming Yang, Toru Kondo, Pooja Dewan, et al.
Cancer Cell|December 18, 2020
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor ImmunityChangzheng Lu, Junhong Guan, Steve Lu, et al.
European Journal of Heart Failure|May 16, 2025
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialMisato Chimura, Mingming Yang, Alasdair D Henderson, et al.
Journal of the American College of Cardiology|August 23, 2023
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart FailureToru Kondo, Xiaowen Wang, Mingming Yang, et al.
European Journal of Heart Failure|August 31, 2024
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
European Journal of Heart Failure|June 26, 2024
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fractionMingming Yang, Toru Kondo, Pardeep S Jhund, et al.
Nature Nanotechnology|September 18, 2023
Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeuticsYifan Wang, Weiye Deng, DaeYong Lee, et al.
European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.
Journal of the American College of Cardiology|November 9, 2024
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFMingming Yang, Alasdair D Henderson, Atefeh Talebi, et al.
Pageof 28